Indeed, recent evidence suggests that increased overall survival of prostate cancer patients treated with Ipilimumab and the vaccine GVAX was associated with increased with pre-treatment levels of CTLA-4+ and PD-1+ T cells in circulation [27]. The gene discussed is CTLA4; the disease is Familial prostate cancer.